This is a routine governance filing with no immediate trading catalyst. The reduced evergreen provision (5% to 4%) marginally lowers future dilution risk, but the impact is negligible for near-term price action. Monitor the next quarterly filing for any changes in share count or compensation expense.
Price Chart
Executive Summary
ORIC Pharmaceuticals filed an 8-K reporting the stockholder-approved amendment and restatement of its 2020 Equity Incentive Plan at the June 18, 2026 annual meeting. Key changes include reducing the annual evergreen increase from 5% to 4% of outstanding shares (removing the 2,656,500-share cap) and eliminating the ability to implement an exchange program. The filing also reports the re-election of directors Jacob M. Chacko, M.D. and Mardi C. Dier, ratification of KPMG as auditor, and an advisory vote supporting annual say-on-pay frequency. This is a routine governance filing with no material financial impact.
Key Facts
- Stockholders approved the amended and restated 2020 Equity Incentive Plan with 61,228,918 votes for, 27,264,875 against, and 1,212,463 abstentions.
- The annual evergreen provision was amended to reduce the annual increase from 5% to 4% of outstanding shares, removing the prior fixed cap of 2,656,500 shares.
- The plan now caps incentive stock option issuance at 10,000,000 shares.
- The administrator's ability to implement an exchange program (cancelling/re-pricing underwater options) was eliminated.
- Directors Jacob M. Chacko, M.D. (89,298,150 for) and Mardi C. Dier (82,007,899 for) were re-elected as Class III directors.
- KPMG LLP was ratified as independent auditor for FY2026 (94,536,096 for, 34,641 against).
- Advisory vote on executive compensation passed with 88,453,809 for, 1,250,074 against.
- Stockholders selected 'every one year' as the frequency for future advisory votes on executive compensation (89,392,979 for one year).
- 94,571,281 shares (91.36% of outstanding) were represented at the meeting.
Financial Impact
No financial figures reported. The plan amendment reduces potential annual dilution from 5% to 4% of outstanding shares, a modest reduction in future equity compensation capacity.
Risk Factors
- The 27.3 million 'against' votes on the equity plan (29% of votes cast) indicate notable shareholder dissent on compensation structure.
- No financial results or guidance were provided in this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-277511 |
| Document: d103876d8k.htm | 0001193125-26-277511 |
| Document: 0001193125-26-277511-index-headers.html | 0001193125-26-277511 |
| Document: 0001193125-26-277511-index.html | 0001193125-26-277511 |
| Document: 0001193125-26-277511.txt | 0001193125-26-277511 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 3, 2026 8w ago | Press Release | $13.47 $12.89 | ▼ −4.31% | ▼ −3.07% | $12.26 (−8.98%) |
Jun 22, 2026 14w ago | 8-K | $8.91 $10.42 | ▲ +16.95% | ▲ +15.79% | $12.26 (+37.60%) |
Jun 11, 2026 16w ago | Institutional Cluster | $7.82 $10.94 | ▲ +39.90% | ▲ +38.01% | $12.26 (+56.78%) |
May 4, 2026 21w ago | 8-K | $9.57 $7.62 | ▼ −20.38% | ▼ −25.33% | $12.26 (+28.11%) |
Apr 3, 2026 25w ago | Press Release | $8.91 $9.63 | ▲ +8.08% | ▼ −0.90% | $12.26 (+37.60%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access